tiprankstipranks
Advertisement
Advertisement

SVRA Stock Latest News

Savara announces EMA validation of MAA for MOLBREEVI
The FlySavara announces EMA validation of MAA for MOLBREEVI
3d ago
SVRA
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
PremiumRatings
De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi
16d ago
SVRA
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
PremiumRatings
Savara: Regulatory Momentum and Strong Phase 3 Data Underpin Buy Rating and $11 Upside Target
17d ago
SVRA
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
PremiumThe Fly
Midday Fly By: Adobe CEO to step down, Meta delays ‘Avocado’ AI model launch
19d ago
BX
MS
Savara Signs Long-Term Lease for New Headquarters
PremiumCompany Announcements
Savara Signs Long-Term Lease for New Headquarters
19d ago
8K
SVRA
Savara reports Q4 EPS (13c), consensus (12c)
PremiumThe FlySavara reports Q4 EPS (13c), consensus (12c)
19d ago
SVRA
Savara announces receipt of Day 74 Letter from FDA
Premium
The Fly
Savara announces receipt of Day 74 Letter from FDA
26d ago
SVRA
Savara says FDA files BLA for Molbreevi
Premium
The Fly
Savara says FDA files BLA for Molbreevi
1M ago
SVRA
Savara announces BLA for Molbreevi filed for review by FDA
PremiumThe Fly
Savara announces BLA for Molbreevi filed for review by FDA
1M ago
SVRA
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
PremiumCompany Announcements
Savara Advances Pediatric aPAP Trial With Inhaled Molgramostim, Extending Its Rare Lung Disease Reach
1M ago
SVRA
Savara Enters New Material Definitive Agreement and Obligation
PremiumCompany Announcements
Savara Enters New Material Definitive Agreement and Obligation
2M ago
8K
SVRA
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
PremiumRatings
Savara (SVRA): Advancing MOLBREEVI Toward Likely FDA Approval and Blockbuster Rare Disease Potential
3M ago
SVRA
Savara Highlights Autoimmune PAP Burden in Updated Presentation
PremiumCompany AnnouncementsSavara Highlights Autoimmune PAP Burden in Updated Presentation
3M ago
8K
SVRA
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
Premium
Ratings
Savara (SVRA): Molbreevi De-Risking and Enhanced aPAP Market Visibility Support Higher Target and Buy Rating
3M ago
SVRA
Savara price target raised to $10 from $8 at H.C. Wainwright
Premium
The Fly
Savara price target raised to $10 from $8 at H.C. Wainwright
3M ago
SVRA
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
PremiumRatings
Savara (SVRA): Buy Rating on High MOLBREEVI Approval Odds and Blockbuster Commercial Potential
3M ago
SVRA
Savara resubmits Molbreevi BLA to the FDA
PremiumThe Fly
Savara resubmits Molbreevi BLA to the FDA
3M ago
SVRA
Savara announces EPO intention to grant Molbreevi patent application
PremiumThe Fly
Savara announces EPO intention to grant Molbreevi patent application
4M ago
SVRA
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
PremiumRatings
Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
4M ago
SVRA
Savara rumor highlighted in Betaville blog
PremiumThe FlySavara rumor highlighted in Betaville blog
4M ago
SVRA
Savara issues patent for Molbreevi from European Patent Office
Premium
The Fly
Savara issues patent for Molbreevi from European Patent Office
4M ago
SVRA
Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
Premium
Ratings
Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement
4M ago
SVRA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >